MedPath

Norethisterone

Generic Name
Norethisterone
Brand Names
Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Emzahh 28 Day, Errin 28 Day, Estalis, Etyqa 0.5/0.1 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Finzala 24 Fe Chewable 28 Day, Fyavolv, Gemmily 28 Day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Rhuzdah 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent
Drug Type
Small Molecule
Chemical Formula
C20H26O2
CAS Number
68-22-4
Unique Ingredient Identifier
T18F433X4S
Background

Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and its derivatives, and is the active form of several other progestins including norethynodrel and lynestrenol. Norethisterone mimics the actions of endogenous progesterone, albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy. First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.

Indication

Norethisterone is indicated as an oral contraceptive when given as monotherapy or in combination with an estrogen component, such as ethinylestradiol or estradiol. In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause. When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.

Norethisterone, taken in combination with intramuscular leuprolide, is also indicated for the symptomatic treatment of endometriosis-related pain.

Associated Conditions
Endometriosis related pain, Heavy Menstrual Bleeding, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Postmenopausal Osteoporosis, Severe Pain, Vulvo Vaginal Atrophy, Hypoestrogenism, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Hormone Replacement Therapy, Oral Contraceptives

Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women

Not Applicable
Completed
Conditions
Endometrial Hyperplasia
Interventions
Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland
First Posted Date
2011-12-26
Last Posted Date
2011-12-26
Lead Sponsor
Mansoura University
Target Recruit Count
120
Registration Number
NCT01499602
Locations
🇪🇬

Mansoura University Hospitals,OB/GYN department, Mansoura, Dakahlia Governorate, Egypt

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Phase 2
Conditions
Secondary-progressive Multiple Sclerosis
Primary-progressive Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis
Interventions
Other: Placebo
Other: Progestin Placebo
First Posted Date
2011-11-06
Last Posted Date
2019-11-06
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
64
Registration Number
NCT01466114
Locations
🇺🇸

The University of Colorado Denver, Aurora, Colorado, United States

🇺🇸

The University of New Mexico, Albuquerque, New Mexico, United States

🇺🇸

The University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Phase 4
Conditions
Heavy Menstrual Bleeding
Menorrhagia
Hypermenorrhea
Interventions
First Posted Date
2011-07-11
Last Posted Date
2011-07-11
Lead Sponsor
Scott and White Hospital & Clinic
Target Recruit Count
80
Registration Number
NCT01391052
Locations
🇺🇸

Scott and White Hospital and Clinic, Temple, Texas, United States

Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia

Not Applicable
Completed
Conditions
Menorrhagia
Interventions
First Posted Date
2010-12-24
Last Posted Date
2010-12-24
Lead Sponsor
Mansoura University
Target Recruit Count
95
Registration Number
NCT01266759
Locations
🇪🇬

Mansoura University Hospitals,OB/GYN department, Mansoura, Dakahlia Governorate, Egypt

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

Phase 2
Completed
Conditions
Alkylating Agents
Lymphoma
Fertility Preservation
Interventions
First Posted Date
2010-07-12
Last Posted Date
2015-10-30
Lead Sponsor
Erasme University Hospital
Target Recruit Count
118
Registration Number
NCT01160315
Locations
🇫🇷

Hôpital Hotel Dieu, Paris, France

🇧🇪

AZ St Jan, Brugges, Belgium

🇧🇪

CHRU Lille, Lille, Belgium

and more 12 locations

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

Phase 3
Completed
Conditions
Contraceptive Usage
Interventions
First Posted Date
2010-06-09
Last Posted Date
2013-09-19
Lead Sponsor
Watson Pharmaceuticals
Target Recruit Count
1659
Registration Number
NCT01140217
Locations
🇺🇸

Watson Investigational Site, Seattle, Washington, United States

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

Not Applicable
Withdrawn
Conditions
Endometrioma
Interventions
First Posted Date
2009-10-21
Last Posted Date
2013-12-10
Lead Sponsor
University of Oklahoma
Registration Number
NCT00999479
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Study of Safety and Efficacy of an Oral Contraceptive

First Posted Date
2009-07-03
Last Posted Date
2013-04-22
Lead Sponsor
Warner Chilcott
Target Recruit Count
938
Registration Number
NCT00932321
Locations
🇺🇸

Warner Chilcott Investigational Site, Seattle, Washington, United States

The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots

Not Applicable
Terminated
Conditions
Women's Health
Blood Coagulation Disorders
First Posted Date
2007-12-24
Last Posted Date
2010-06-28
Lead Sponsor
University of Vermont
Target Recruit Count
20
Registration Number
NCT00580424
Locations
🇺🇸

University of Vermont, Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath